{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:58:23Z","timestamp":1780527503931,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.transproceed.2019.05.023","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T20:38:10Z","timestamp":1573591090000},"page":"3275-3280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases"],"prefix":"10.1016","volume":"51","author":[{"given":"Nizar","family":"Attallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.transproceed.2019.05.023_bib1","first-page":"A71","article-title":"US Renal Data System 2017 Annual Data Report: epidemiology of kidney disease in the United States","volume":"71","author":"Saran","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2019.05.023_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.05.023_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1046\/j.1523-1755.2001.059002732.x","article-title":"Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years","volume":"59","author":"Cosio","year":"2001","journal-title":"Kidney Int"},{"issue":"10 Suppl","key":"10.1016\/j.transproceed.2019.05.023_bib4","first-page":"SS3","article-title":"International expert panel - new-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2019.05.023_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1399-0012.2005.00359.x","article-title":"Guidelines for the treatment and management of new-onset diabetes after transplantation","volume":"19","author":"Wilkinson","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2019.05.023_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00007890-198902000-00016","article-title":"Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients","volume":"47","author":"Roth","year":"1989","journal-title":"Transplantation"},{"issue":"11 Suppl","key":"10.1016\/j.transproceed.2019.05.023_bib7","first-page":"SS58","article-title":"Impact and management of posttransplant diabetes mellitus","volume":"70","author":"Jindal","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2019.05.023_bib8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/ndt\/16.8.1545","article-title":"Causes of death after renal transplantation","volume":"16","author":"Briggs","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2019.05.023_bib9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.05.023_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.1600-6143.2003.00315.x","article-title":"The burden of chronic kidney disease in renal transplant recipients","volume":"4","author":"Karthikeyan","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.05.023_bib11","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"ELITE-Symphony Study reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.transproceed.2019.05.023_bib12","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.05.023_bib13","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/diacare.25.12.2359","article-title":"Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy","volume":"25","author":"Kasayama","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.transproceed.2019.05.023_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register","volume":"2","author":"Ekstr\u00f6m","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.transproceed.2019.05.023_bib15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1600-6143.2006.01250.x","article-title":"Repaglinide in the management of new-onset diabetes mellitus after renal transplantation","volume":"6","author":"T\u00fcrk","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.05.023_bib16","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ndt\/gft536","article-title":"Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation","volume":"29","author":"Str\u00f8m Halden","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2019.05.023_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/ajt.12518","article-title":"Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Haidinger","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.05.023_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1681\/ASN.2011080835","article-title":"Early basal insulin therapy decreases new-onset diabetes after renal transplantation","volume":"23","author":"Hecking","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2019.05.023_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.transproceed.2019.05.023_bib20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.transproceed.2019.05.023_bib21","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.05.023_bib22","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.transproceed.2019.05.023_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.05.023_bib24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.05.023_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.05.023_bib26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.05.023_bib27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.transproceed.2019.05.023_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium\u2013glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.transproceed.2019.05.023_bib29","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.transproceed.2019.05.023_bib30","first-page":"844","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.transproceed.2019.05.023_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2019.05.023_bib32","doi-asserted-by":"crossref","first-page":"26428","DOI":"10.1038\/srep26428","article-title":"Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice","volume":"6","author":"Gallo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.transproceed.2019.05.023_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.transproceed.2019.05.023_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transproceed.2019.05.023_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519300399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519300399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:33:51Z","timestamp":1758576831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134519300399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0041134519300399"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.05.023","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}